[JNJ] Johnson & Johnson: Can New Drugs Offset STELARA?

Johnson & Johnson sells innovative medicines and medical technology, and it is scheduled to report the Fiscal third quarter 2026 ended September 27, 2026 on 2026-10-13.[1] Second-quarter sales were $25.31 billion, up 5.6% operationally; Innovative Medicine generated $16.4 billion with 6.8% operational growth, while MedTech generated $8.9 billion with 3.6% growth. Management raised full-year operational sales growth guidance to 6.5%–7.1%, with a $100.6 billion midpoint, and expects roughly 75 basis points of adjusted pretax operating margin improvement and free cash flow approaching $21 billion.[2]

Three items matter most in the next report. First, Innovative Medicine must hold above its 6.8% second-quarter growth rate while absorbing a 760-basis-point STELARA drag because it supplies about two-thirds of revenue and most segment profit. Second, MedTech needs to accelerate from 3.6% and show that China inventory and Abiomed pressure are temporary. Third, operating cash flow must absorb the dividend, launch investment, orthopaedics separation and talc costs while preserving the path to roughly $21 billion of full-year free cash flow.[2][3]

Company Background and Business Structure

Johnson & Johnson is a global healthcare company that has reported only Innovative Medicine and MedTech since separating consumer-health company Kenvue in 2023. Fiscal 2025 sales were $94.193 billion and worldwide income before tax was $32.581 billion; management says 28 products or platforms now generate more than $1 billion each in annual sales.[4]

Innovative Medicine is the main profit engine, with fiscal 2025 sales of $60.401 billion, 64.1% of the company total, and $22.266 billion of segment pretax income, a 36.9% margin versus 33.2% a year earlier. DARZALEX, STELARA, TREMFYA and the INVEGA family generated $14.351 billion, $6.078 billion, $5.155 billion and $3.810 billion. MedTech produced $33.792 billion of sales and $4.113 billion of segment pretax income at a 12.2% margin; electrophysiology, general surgery, advanced surgery and contact lenses are major lines, while orthopaedics is being prepared for separation.[4]

Financial History and Current Position

Revenue has risen steadily since the Kenvue separation, from $85.159 billion in fiscal 2023 to $88.821 billion in 2024 and $94.193 billion in 2025, a 6.0% increase in the latest year. Fiscal 2025 gross profit was $68.558 billion, or 72.8% of sales, while operating income rose to $25.596 billion from $22.149 billion in 2024; research and development expense was $14.665 billion.[4]

Reported net income is heavily affected by litigation accounting: it was $35.153 billion, $14.066 billion and $26.804 billion in fiscal 2023–2025, with diluted EPS of $13.72, $5.79 and $11.03. Roughly $5.1 billion of talc charges depressed 2024, while a roughly $7.0 billion reserve reversal lifted 2025, so the annual profit series is not a clean operating trend.[4]

Cash flow has been steadier, with operating cash flow of $22.791 billion, $24.266 billion and $24.530 billion across those three years. Fiscal 2025 free cash flow was $19.698 billion after $4.832 billion of capital expenditure and covered $12.381 billion of dividends, but total debt rose from $29.332 billion at the end of 2023 to $47.933 billion at the end of 2025, while net debt rose from $7.473 billion to $28.224 billion.[4]

The first half of 2026 combined higher sales and operating profit with sequentially better free cash flow. First-quarter sales, operating income and diluted EPS were $24.062 billion, $6.395 billion and $2.14, followed by $25.310 billion, $7.174 billion and $2.27 in the second quarter; free cash flow improved from $1.465 billion to $3.390 billion. Net debt was $28.6 billion on June 28, against $20.758 billion of cash and marketable securities.[3][5][6]

Operating Model

Revenue combines two volume, price and mix systems. Innovative Medicine sales equal prescription volume times net price across oncology, immunology, neuroscience and other franchises, while MedTech sales reflect procedure volume times price and mix across cardiovascular, surgery, vision and orthopaedics; reported operational growth excludes currency, and fiscal 2026's 53rd week contributes about 100 basis points.[2]

Profit begins with those sales less product costs, commercial expense, R&D and restructuring, acquisition and separation items. Consolidated pretax income then subtracts corporate interest and litigation, including talc, that is not allocated to segments. Management's adjusted pretax margins exclude amortization and selected special items, so they are not directly comparable with filing-based segment margins.[2][4]

Cash provides the final test of earnings quality because operating cash flow also reflects working capital, taxes and litigation payments, while free cash flow subtracts capital expenditure. That cash must fund dividends, bolt-on deals and the orthopaedics separation, with any shortfall appearing in net debt; product-level profit is not disclosed, so the margin on launches replacing STELARA cannot yet be observed directly.[3][4]

Industry and Competitive Position

Johnson & Johnson's position rests on scale across both medicines and devices, spanning oncology, immunology, electrophysiology, surgery, vision and orthopaedics. Its medicines still face the loss-of-exclusivity cycle common to large drugmakers, with STELARA now under biosimilar pressure, while its devices face procedure cycles, Chinese volume-based procurement pricing and platform competition; OTTAVA is a late entrant in surgical robotics.[2][4]

The company's competitive goals still depend on future products delivering. Management aims to rank first in oncology by 2030 with more than $50 billion of oncology sales and expects OTTAVA and Monarch for Urology to become meaningful MedTech contributors by the end of the decade; without product-level profit disclosure, investors cannot yet see whether that scale will raise segment profitability.[2]

Core Debates

Can Innovative Medicine reaccelerate past the STELARA biosimilar erosion on oncology and new launches?

Innovative Medicine's growth determines whether the company can meet its raised full-year guide because the segment supplies roughly two-thirds of revenue and most segment profit. In the second quarter it grew 6.8% operationally despite a 760-basis-point STELARA drag, and management said the remaining 96% of the segment grew more than 14%; STELARA declined 55.7%, TREMFYA grew 71%, and Icotide had reached more than 11,000 patients and 6,000 prescribers.[2]

The unresolved issue is growth quality because adjusted pretax margin slipped from 42.7% to 42.5% on mix and launch spending. Third-quarter growth above 6.8%, no further expansion in the STELARA drag, continued Icotide adoption and a stable margin would strengthen the replacement case; slower launches or persistently lower margins on replacement revenue would weaken it.[2]

Does MedTech reaccelerate in the second half once the China inventory drag and Abiomed caution fade?

MedTech growth and margin determine whether the company can create operating leverage outside medicines because the business provides about one-third of revenue but posted only a 12.2% filing-based pretax margin in fiscal 2025. Second-quarter operational growth was 3.6%, cardiovascular grew 3.1% despite a 400-basis-point China inventory drag and a 2% Abiomed decline, and VariPulse had treated more than 85,000 patients; adjusted pretax margin slipped from 22.2% to 22.0%.[2][4]

Third-quarter evidence must establish whether those pressures were temporary. Growth above 3.6%, a return to growth at Abiomed, no repeat of the China drag and confirmed OTTAVA or Monarch launches would support recovery; continuing Chinese price pressure or physician caution through the 2027 PROTECT4 readout would falsify it.[2]

Is the roughly $3.4 billion talc reserve enough now that the claims are back in the tort system?

Talc is large enough to change consolidated profit on its own, so a strong operating quarter can still be offset below the segment line. The reserve had a present value of roughly $3.4 billion at fiscal 2025 year-end, about one-third current; the company then recorded $0.3 billion and $0.4 billion of charges in the first and second quarters of 2026, while second-quarter income and expense not allocated to segments was a $679 million expense versus $265 million a year earlier.[3][4][5]

The reserve is an accrued amount, not a loss cap, because management says it cannot estimate possible loss beyond recorded amounts. A stable reserve, a third-quarter charge no higher than $0.4 billion and lower unallocated expense would support the present view; repeated adverse verdicts, a reserve increase or rising charges would weaken it through both pretax earnings and eventual cash payments.[3]

Can free cash flow reach roughly $21 billion while the dividend, launches, deals and the orthopaedics separation all draw on it?

The cash debate places growth investment and capital commitments under one constraint. Fiscal 2025 operating cash flow was $24.530 billion, capital expenditure was $4.832 billion, free cash flow was $19.698 billion and dividends were $12.381 billion; second-quarter cash and marketable securities were about $21 billion against $49 billion of debt, while management still expects full-year free cash flow approaching $21 billion.[2][4]

The orthopaedics separation adds uncertainty over both timing and funding, with $0.3 billion of costs in the second quarter and $0.4 billion in the first half. Nine-month free cash flow, roughly $28 billion of net debt, separation costs and the mid-2027 timetable will test the guide; the path would weaken if talc payments, separation costs and launch spending cluster together or deals increase net debt faster than cash flow reduces it.[3]

Risks and Falsifiers

The clearest operating risk is that launch growth slows before the STELARA drag fully annualizes, or that replacement products carry persistently lower margins. Third-quarter Innovative Medicine growth below 6.8%, a drag greater than 760 basis points and another margin decline would turn that possibility into observable contrary evidence.[2]

MedTech faces the risk that China pressure reflects lasting price cuts rather than inventory timing, that Abiomed caution lasts into 2027 or that platform launches slip. Failure to exceed 3.6% growth, another roughly 400-basis-point cardiovascular drag and no initial platform placements would weaken the recovery case.[2]

Consolidated results face the combined risk of talc verdicts and overlapping cash demands. A reserve above roughly $3.4 billion, quarterly talc expense materially above $0.4 billion, or free cash flow falling off the roughly $21 billion path while net debt rises above roughly $28 billion would respectively falsify the current litigation and cash-compatibility views.[2][3][4]

What to Watch Next

• For Innovative Medicine, compare operational growth with 6.8%, the STELARA drag with 760 basis points and adjusted pretax margin with 42.5%; faster growth with stable margin confirms the bridge, while slower launches and another margin decline weaken it.
• For MedTech, compare segment and cardiovascular growth with 3.6% and 3.1%, then track China inventory, Abiomed and OTTAVA or Monarch placements; fading pressure confirms recovery, while lasting pricing or caution falsifies it.
• For talc, track the roughly $3.4 billion reserve, the $0.4 billion quarterly charge and $679 million of unallocated expense; stable accruals support the current view, while adverse verdicts and a step-up in accruals undermine it.
• For cash, compare nine-month free cash flow with the roughly $21 billion full-year path, net debt with roughly $28 billion and separation costs with $0.3 billion in the latest quarter; stable leverage confirms compatibility, while clustered costs and rising debt weaken it.

Conclusion

Johnson & Johnson's results are driven by prescription volume and net price in medicines and procedure volume and mix in MedTech, while usable cash must also absorb taxes, working capital, litigation and capital expenditure. Second-quarter sales reached $25.31 billion with 5.6% operational growth, but adjusted pretax margins edged lower in both segments and net debt stood near $28.6 billion. The central relationship is therefore not revenue growth alone, but whether replacement products can preserve margins and cash flow during an investment-heavy period.[2][3]

Two independent interpretations change the boundaries around litigation and portfolio reshaping. Reuters reported that a federal judge required roughly 69,000 ovarian-cancer claimants to provide more specific evidence or face dismissal, suggesting the funded claim pool may be smaller than the headline docket without proving the $3.4 billion reserve is sufficient.[7] Stocktwits reported that Apollo was discussing an orthopaedics acquisition at at a transaction value of about $20 billion and that the MedTech chair would choose between a spin-off and sale based on value; the alternatives imply different cash, timing and leverage outcomes.[8]

The current view would strengthen if Innovative Medicine and MedTech accelerate together, both margins stabilize, talc charges and reserves avoid a step-up, and nine-month cash flow supports the roughly $21 billion full-year target. It would weaken if replacement-product margins keep falling, China or Abiomed pressure persists, litigation accruals rise, and separation costs and net debt increase at the same time.

Sources

[1] JNJ earnings calendar updated 2026-09-12 · 2026-09-12 · 8-K · https://www.investor.jnj.com/events-and-presentations/default.aspx

[2] JNJ Q2 2026 earnings call 2026-07-15 · 2026-07-15 · earnings call · https://www.investor.jnj.com/events-and-presentations/default.aspx

[3] JNJ Q2 2026 10-Q filed 2026-07-23 · 2026-07-23 · 10-Q · https://www.sec.gov/Archives/edgar/data/200406/000020040626000123/0000200406-26-000123-index.htm

[4] JNJ FY2025 10-K filed 2026-02-11 · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/0000200406-26-000016-index.htm

[5] JNJ Q1 2026 earnings call 2026-04-14 · 2026-04-14 · earnings call · https://www.investor.jnj.com/events-and-presentations/default.aspx

[6] JNJ Q1 2026 10-Q filed 2026-04-22 · 2026-04-22 · 10-Q · https://www.sec.gov/Archives/edgar/data/200406/000020040626000087/0000200406-26-000087-index.htm

[7] Reuters talc MDL report 2026-07-22 · 2026-07-22 · Reuters · https://www.reuters.com/legal/government/us-judge-casts-doubt-69000-cases-alleging-jj-talc-caused-cancer-2026-07-22/

[8] Stocktwits Apollo orthopaedics report 2026-09-11 · 2026-09-11 · Stocktwits · https://stocktwits.com/news-articles/markets/equity/jnj-stock-edges-up-after-hours-on-apollo-s-20-b-orthopedics-talks/cZtXy60RBbk